Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,225 JPY | +0.62% | +5.90% | +3.03% |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 36.56 and 26.44 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.92 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.03% | 1.5B | - | ||
+2.92% | 49.79B | A- | ||
+19.98% | 42.5B | B+ | ||
+23.07% | 26.45B | A- | ||
+12.04% | 19.66B | C+ | ||
+0.75% | 17.18B | B+ | ||
-24.51% | 15.82B | A- | ||
+3.42% | 15.56B | B+ | ||
-9.92% | 15.41B | C+ | ||
-18.80% | 13.67B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 5384 Stock
- Ratings Fujimi Incorporated